The IPO Buzz: Scribe Therapeutics Upsizes IPO & Prices it at $15 – Top of Range

Scribe Therapeutics  (SCTX) upsized its IPO at pricing to 8.58 million shares – up from 7.15 million in the prospectus – and priced the deal at $15.00 – the top of its range – to raise $128.7 million on Thursday night, July 23, 2026. The Phase 1 cardiovascular-focused biotech had marketed its IPO at a price range of $13.00 to $15.00. Scribe’s stock is expected to start trading on Friday, July 24, on the NASDAQ.

Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities were the joint book-runners of Scribe’s IPO.

Scribe also raised $7.5 million by selling 500,000 shares at $15.00 each – the IPO price – to Sanofi in a private placement.

Eli Lilly had indicated that it would buy stock in the IPO that – combined with the stock it already owns – would give it a 10.9 percent stake in Scribe, the prospectus said.

Scribe Therapeutics’ own epigenetic silencing technology is based on a novel CRISPR CasX enzyme, the prospectus said. The technology is being used to develop STX-1150, Scribe’s leading drug candidate – an IV infusion designed to cut  high levels of “bad” cholesterol. A single dose is expected to last for up to four years. Scribe expects to provide results from its Phase 1 clinical trial of STX-1150 in the first half of 2027.

Dr. Jennifer A. Doudna, a co-founder of Scribe Therapeutics, shared a Nobel Prize in 2020 for the groundbreaking discovery of CRISPR-based genome editing.

Scribe Therapeutics, based in Alameda, California, is also using its own gene-editing technology to develop two more drug candidates – STX-1200 to lower “bad” cholesterol and STX-1400 to reduce high levels of triglycerides. These drugs will be delivered by injection. Results from Phase 1 clinical trials of these two drug candidates are expected in 2027 and 2028, the prospectus said.

In the prospectus, Scribe points out that the buildup of “bad” cholesterol in the arteries and high levels of triglycerides are factors in atherosclerotic cardiovascular disease (ASCVD), which can cause heart attacks and death, the prospectus said.

Scribe is not profitable: Net loss of $35.73 million on collaboration revenue of $36.28 million for the 12 months that ended on March 31, 2026, the prospectus said.

(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)

Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.

To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.

Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.